Blanket Purchase Agreement 36F79720D0169-36E79721A0026
Award Date 10/1/21
Last Date to Order 9/30/26
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed Similar IDVs
- The federal contract IDV award is a multiple award Federal Supply Schedule (FSS) contract under the Pharmaceuticals and Drugs category (FSS-61-IB), with a ceiling value of $78,000,000.00. The contract was awarded by the U.S. Department of Veterans Affairs (VA) Veterans Health Administration to Sobi, Inc., a foreign-owned, for-profit pharmaceutical company. The FSS contract, along with a single award Blanket Purchase Agreement (BPA) also held by Sobi, Inc. under the same schedule, allows the VA...
- This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Amryt Pharmaceuticals Inc., a foreign-owned, for-profit organization, on November 5, 2022. The potential value of the BPA is $1,000,000. No set-aside was used. The BPA is for a single award and permits ordering of Mycapssa, Juxtapid, and Myalept through March 14, 2024. Mycapssa, Juxtapid, and Myalept are pharmaceutical products used to treat certain rare diseases. The Department of...
- This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to Nobelpharma America, LLC, a foreign-owned, self-certified small disadvantaged business. The single-award BPA, valued at up to $4.5 million, is for the delivery of the medication HYFTOR through June 2026. HYFTOR is likely used to treat conditions like post-traumatic stress disorder and chronic pain among veterans. In addition to this BPA, Nobelpharma America, LLC...
- This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to Gilead Sciences Inc., a large biopharmaceutical company, to provide specialized pharmaceutical products including Letairis, Yescarta, and Tecartus. The single-award BPA, valued at $29,160,000.00, runs through October 31, 2026 and is structured under the Pharmaceuticals and Drugs (FSS-61-IB) General Services Administration (GSA) Schedule. This contract vehicle enables...
- This single-award Blanket Purchase Agreement, valued at $3.16 million, was awarded by the U.S. Department of Veterans Affairs National Acquisition Center to Recordati Rare Diseases Inc. on July 13, 2021, with a performance period extending through July 12, 2026. The BPA is established under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and contains no set-aside designations. The contract provides the VA with a streamlined procurement mechanism for five specialized...
- This Blanket Purchase Agreement (BPA) was awarded by the National Acquisition Center, a civilian agency within the U.S. federal government, to Takeda Pharmaceuticals America Inc., a foreign-owned, for-profit manufacturer of specialized pharmaceutical products. The BPA, valued at $131,039,520.00, is a single-award contract that falls under the General Services Administration (GSA) Pharmaceuticals and Drugs Schedule. It enables the procurement of various critical medications such as CINRYZE,...
- This Blanket Purchase Agreement (BPA) was awarded by the U.S. Department of Veterans Affairs (VA) National Acquisition Center to United Therapeutics Corporation, a self-certified small disadvantaged business and for-profit manufacturer of pharmaceutical goods. The BPA has a ceiling value of $207,127,385 and a performance period extending through April 2026. It allows the VA to procure specialized pharmaceutical products from United Therapeutics' portfolio, including Orenitram, Remodulin, Tyvaso,...
- The U.S. Department of Veterans Affairs (VA) has awarded Takeda Pharmaceuticals America, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, a Blanket Purchase Agreement (BPA) valued at $123.5 million under the company's General Services Administration (GSA) Schedule 61-IB for Pharmaceuticals and Drugs. This single-award BPA allows various VA medical facilities and Veterans Integrated Service Networks (VISNs) to place delivery orders for the specialty oncology medication ICLUSIG...
- This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs National Acquisition Center to Idorsia Pharmaceuticals US Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals and related products. The $3.1 million single-award contract establishes an Indefinite Delivery Vehicle (IDV) for the procurement of orexin inhibitors, a class of sleep-regulating medications, over a one-year base period with four option years. This BPA aims to ensure the availability of...
- This Blanket Purchase Agreement (BPA) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Provention Bio Inc., a biopharmaceutical company, to provide the drug TZIELD. The single-award BPA has a ceiling value of $1,444,167.20 and a period of performance from January 2023 through July 2023. This BPA was issued against Provention Bio's 5-year, $5 million Federal Supply Schedule (FSS) contract under Schedule 65 I B for drugs, pharmaceuticals and...
Name | Description | Awardee | Potential Value | AwardDate | CompletionDate | Updated At |
|---|---|---|---|---|---|---|
BPA Call 36E79721A0026-36C25022N0640 | Sobi, Inc. | $105.2k | 6/15/22 | 9/30/22 | 6/14/22 |